Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Neuroendocrine tumors (NETs)

Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Neuroendocrine tumors (NETs) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells. There are many types of neuroendocrine tumors, but most are classified as one of two main types:

Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes, brain, bone, gonads (ovaries and testes) or skin.

Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas.

A pheochromocytoma is another, rarer type of NET that usually develops in the adrenal gland, but can also arise in other parts of the body. According to Thelansis estimates, Each year 5.25 out of every 100,000 people in the United States are diagnosed with NET.

Competitive landscape of Neuroendocrine tumors (NETs) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Neuroendocrine tumors (NETs) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Neuroendocrine tumors (NETs) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 

S. No        Asset        Company        Partner        Phase

1        Afinitor        Novartis AG        N/A        Approved (Generic Competition)

2        Sandostatin        Novartis AG        N/A        Approved (Generic Competition)

3        Azedra        Progenics Pharmaceuticals, Inc.        N/A        Approved

4        Demser        Bausch Health Companies Inc.        Ono Pharmaceutical Company        Approved

5        Lutathera        Novartis AG        FUJIFILM        Approved

6        Sandostatin LAR        Novartis AG        N/A        Approved

7        Somatuline Autogel        Ipsen SA        Teijin Pharma        Approved

8        Sutent        Pfizer Inc.        N/A        Approved

9        Unituxin        United Therapeutics Corporation        N/A        Approved

10        Xermelo        TerSera Therapeutics LLC        Ipsen        Approved

11        Danyelza        Y-mAbs Therapeutics Inc.        Memorial Sloan Kettering        BLA

12        EndolucinBeta        ITM Isotopen Technologien München AG        DuChemBio; POINT        III

13        Qarziba        EUSA Pharma Ltd.        Medison; Gen Ilac; Endo International; Apeiron; BeiGene        III

14        ABI-009        AADi Bioscience, LLC        Bristol Myers Squibb        II

15        CPP-1X        Cancer Prevention Pharmaceuticals, Inc.        N/A        II

16        GD2-GD3 Vaccine        Y-mAbs Therapeutics Inc.        MabVax        II

17        Keytruda        Merck & Co., Inc.        DRI Capital        II

18        ONC201        Oncoceutics, Inc.        Ohara Pharmaceutical; NCI        II

19        RRx-001        EpicentRx, Inc.        SciClone Phaarmaceuticals        II

20        Zybrestat (Injectable)        Mateon Therapeutics, Inc        Azanta        II

21        13-CRA        Nova Laboratories Limited        N/A        I/II

22        9-ING-41        Actuate Therapeutics, Inc.        Northwestern        I/II

23        PEN-221        Tarveda Therapeutics, Inc.        N/A        I/II

24        Rozlytrek        Roche Holding AG        SARI; Chugai Pharmaceutical        I/II

25        Sulfatinib        Hutchison China MediTech Limited        N/A        I/II

26        Vorolanib        Xcovery, Inc.        N/A        I/II

27        AlphaMedix        RadioMedix, Inc.        Orano Med        I

28        AUTO6        Autolus Therapeutics plc        N/A        I

29        BOLD-100        Bold Therapeutics, Inc.        Intezyne        I

30        Ceclazepide        Trio Medicines Ltd        N/A        I

31        CLR 131        Cellectar Biosciences, Inc.        N/A        I

32        CMD-501        Kuur Therapeutics        Baylor College of Medicine        I

33        DP1038        Dauntless Pharmaceuticals, Inc.        N/A        I

34        Glide Octreotide        Enesi Pharma Limited        N/A        I

35        Kimozo        Orphelia Pharma SA        Gustave Roussy        I

36        Lorbrena        Pfizer Inc.        N/A        I

37        PV-10        Provectus Biopharmaceuticals, Inc.        Boehringer Ingelheim        I

38        SF1126        SignalRx Pharmaceuticals, Inc        N/A        I

39        SOMTher        Ipsen SA        N/A        I

40        TBR-760        Tiburio Therapeutics, Inc.        Ipsen        I

41        Venclexta        AbbVie Inc.        Roche        I

42        XmAb18087        Xencor, Inc.        N/A        I

43        Cabometyx / Cometriq        Exelixis, Inc.        Swedish Orphan Biovitrum        Investigator Initiated

44        Dacogen        Otsuka Holdings Co., Ltd.        Johnson & Johnson        Investigator Initiated

45        JCAR023        Bristol-Myers Squibb Company        N/A        Investigator Initiated

46        Temodar        Merck & Co., Inc.        N/A        Investigator Initiated

47        CAM2029        Novartis AG        Camurus        Development Outside U.S.

48        F-1614        FUJIFILM Holdings Corp.        N/A        Development Outside U.S.

49        ABTL0812        Ability Pharmaceuticals, SL        Laminar Pharmaceuticals; SciClone Phaarmaceuticals        Preclinical

50        AK-01        Eli Lilly and Company        N/A        Preclinical

51        Kevetrin        Innovation Pharmaceuticals Inc.        MD Anderson Cancer Center        Preclinical

52        OTS167        OncoTherapy Science, Inc.        N/A        Preclinical

53        SNIPER Antibody Program (Invenra/WARF)        Invenra, Inc.        Wisconsin Alumni Research Foundation        Preclinical

54        SVV-001        Seneca Therapeutics, Inc.        N/A        Preclinical